BPC-157: Peptide Profile, CAS & Properties
CAS 137525-51-0 · 1419.56 g/mol
BPC-157 (CAS 137525-51-0) is a synthetic 15-amino-acid pentadecapeptide (Body Protection Compound 157, PL 14736), molecular formula C62H98N16O22, ~1419.56 g/mol. Studied preclinically for cytoprotective and tissue-repair effects, it is not FDA/EMA approved and was placed in FDA Category 2 in 2023. This page provides reference information on BPC-157.
- CAS Number
- 137525-51-0
- Molecular Formula
- C62H98N16O22
- Molecular Weight
- 1419.56 g/mol
- Drug Class
- pentadecapeptide (body-protection compound)
What is BPC-157?
BPC-157 (Body Protection Compound 157, also designated PL 14736) is a synthetic pentadecapeptide of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The sequence corresponds to a partial fragment derived from a protein identified in human gastric juice. Its molecular formula is C62H98N16O22 with a molecular weight of approximately 1419.56 g/mol (CAS 137525-51-0).
In preclinical research the peptide has been studied for cytoprotective, angiogenic and tissue-repair related effects, predominantly in animal and in-vitro models. The current regulatory position is unambiguous: BPC-157 is not approved by the FDA, EMA or any other drug regulatory agency for human therapeutic use. In 2023 the US FDA placed it in Category 2 of its interim policy on bulk substances used in compounding, citing immunogenicity and impurity concerns, and it has no USP/NF monograph. No efficacy or therapeutic-benefit claims are established for this molecule.
How BPC-157 Is Produced & Characterised
As a 15-residue linear peptide rich in proline (three consecutive Pro residues) and acidic Asp/Glu residues, BPC-157 presents synthesis challenges around coupling efficiency, aspartimide formation and the resolution of closely related deletion and isomerisation sequences. For peptides of this class, the typical industry route is Fmoc solid-phase peptide synthesis (SPPS) with controlled coupling chemistry to suppress these side reactions, followed by purification on preparative HPLC (commonly dynamic axial compression, DAC, columns) to isolate the target sequence from related impurities, and lyophilisation to a stable powder.
Characterisation generally relies on UPLC/HPLC for purity, LC-MS for identity and minor structural-variant profiling, and determination of water content, counter-ion (salt) content, residual solvents and peptide content so the material is fully defined. These are general analytical conventions for synthetic peptides and are described here as reference information.
Typical Quality Specifications
Synthetic peptide reference materials in this class are commonly released against a defined specification. Purity for research-grade material is typically reported at ≥99.0% by UPLC/HPLC, with individual impurities controlled below 0.10%, with identity and impurity profile confirmed by LC-MS. Physical form is usually a white to off-white lyophilised powder.
Stability is generally assessed under ICH Q1A(R2) long-term and accelerated conditions, and analytical methods are typically validated to ICH Q2(R1). The figures above describe representative specifications reported for this molecule and are provided for educational reference only; they are not an offer of supply.
Regulatory Context
BPC-157 is not an approved active pharmaceutical ingredient. It carries no USP/NF monograph and no marketing authorisation from the FDA, EMA or any other drug regulatory agency for therapeutic use. In 2023 the US FDA placed BPC-157 in Category 2 of its interim policy on bulk drug substances used in compounding, citing immunogenicity and impurity concerns.
Because no regulatory therapeutic pathway exists for this molecule, there is no associated US-DMF or CTD Module 3 dossier, and it is encountered only as a research chemical or reference standard. This section summarises the molecule's regulatory status for reference purposes and is not medical, dosing or purchasing advice.
BPC-157 API — Specifications
| CAS Number | 137525-51-0 |
|---|---|
| Molecular Formula | C62H98N16O22 |
| Molecular Weight | 1419.56 g/mol |
| Sequence | 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) |
| Drug Class | Synthetic pentadecapeptide (body-protection compound) |
| Appearance | White to off-white lyophilised powder |
| Typical Purity (HPLC) | ≥ 99.0% (single impurity < 0.10%) |
| Synthesis Route | Fmoc SPPS + preparative HPLC purification |
| Regulatory Status | Not FDA/EMA approved; FDA Category 2 (2023); no USP/NF monograph |
| Form | Lyophilised powder |
Reference data only — WinHyCare neither supplies nor manufactures this compound; see our Semaglutide API for the product we supply. Regulatory status: Not approved by the FDA, EMA or any other drug regulatory agency for therapeutic use. Handled only as a research / reference-standard material. In 2023 the US FDA placed BPC-157 in Category 2 of its interim compounding bulk-substances policy, citing immunogenicity and impurity concerns; it has no USP/NF monograph and no marketing authorisation.
BPC-157 API — Frequently Asked Questions
What is BPC-157?
BPC-157 (Body Protection Compound 157, also designated PL 14736) is a synthetic 15-amino-acid pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its sequence corresponds to a partial fragment of a protein identified in human gastric juice, and it has been studied in preclinical tissue-repair research.
What is the CAS number and molecular weight of BPC-157?
BPC-157's CAS number is 137525-51-0, its molecular formula is C62H98N16O22, and its molecular weight is approximately 1419.56 g/mol.
Is BPC-157 approved?
No. BPC-157 is not approved by the FDA, EMA or any other drug regulatory agency for therapeutic use, and it has no USP/NF monograph or marketing authorisation. In 2023 the US FDA placed it in Category 2 of its interim compounding bulk-substances policy, citing immunogenicity and impurity concerns.
What class of peptide is BPC-157?
BPC-157 is a synthetic pentadecapeptide — a 15-amino-acid linear peptide known as a body-protection compound. It is notably proline-rich, containing three consecutive proline residues alongside acidic aspartate and glutamate residues.
What is BPC-157 being studied for?
In preclinical research, BPC-157 has been investigated for cytoprotective, angiogenic and tissue-repair related effects, predominantly in animal and in-vitro models. No therapeutic efficacy in humans has been established and it remains unapproved.
How is BPC-157 typically produced?
Peptides of this class are typically produced by Fmoc solid-phase peptide synthesis (SPPS) with controlled coupling chemistry to suppress aspartimide formation and deletion sequences, followed by preparative HPLC purification and lyophilisation to a stable powder. This describes the general industry route rather than any specific supplier's process.
Related Peptide APIs
TB-500 (Thymosin Beta-4) API
CAS 77591-33-4
Growth & MetabolismSermorelin API
CAS 86168-78-7
Growth & MetabolismCJC-1295 API
CAS 863288-34-0
Growth & MetabolismTesamorelin API
CAS 218949-48-5
Technical Reference Page
WinHyCare neither supplies nor manufactures BPC-157; this page is provided as a technical reference. The peptide API we supply is Semaglutide.